|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Tumors were classified as high GDF11 expression (n=65) or low GDF11 expression (n=65).
|
17912435 |
2007 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time reverse transcription-PCR in colorectal cancer specimens obtained from 130 patients showed that GDF11 mRNA expression in cancer tissue was significantly higher than in normal tissue (p=0.001).
|
17912435 |
2007 |
|
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Although multivariate analysis showed that GDF11 was not an independent prognostic factor, these findings suggest that GDF11 may be a novel diagnostic and prognostic biomarker in patients with colorectal cancer.
|
17912435 |
2007 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Quantitative real-time reverse transcription-PCR in colorectal cancer specimens obtained from 130 patients showed that GDF11 mRNA expression in cancer tissue was significantly higher than in normal tissue (p=0.001).
|
17912435 |
2007 |
|
Malignant neoplasm of colon and/or rectum
|
0.030 |
Biomarker
|
disease |
BEFREE |
Although multivariate analysis showed that GDF11 was not an independent prognostic factor, these findings suggest that GDF11 may be a novel diagnostic and prognostic biomarker in patients with colorectal cancer.
|
17912435 |
2007 |
|
Colorectal Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Clinical significance of growth differentiation factor 11 in colorectal cancer.
|
17912435 |
2007 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients whose tumors had high GDF11 expression showed a high frequency of lymph node metastasis (p=0.049) and had more cancer-related deaths (p=0.040).
|
17912435 |
2007 |
|
Agenesis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We show that GDF11 is cleaved and activated by PCSK5A, but not by PCSK5A-C470R, and that Gdf11-deficient embryos, in addition to having anteroposterior patterning defects and renal and palatal agenesis, also have a presacral mass, anorectal malformation, and exomphalos.
|
18519639 |
2008 |
|
Congenital omphalocele
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We show that GDF11 is cleaved and activated by PCSK5A, but not by PCSK5A-C470R, and that Gdf11-deficient embryos, in addition to having anteroposterior patterning defects and renal and palatal agenesis, also have a presacral mass, anorectal malformation, and exomphalos.
|
18519639 |
2008 |
|
Congenital exomphalos
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We show that GDF11 is cleaved and activated by PCSK5A, but not by PCSK5A-C470R, and that Gdf11-deficient embryos, in addition to having anteroposterior patterning defects and renal and palatal agenesis, also have a presacral mass, anorectal malformation, and exomphalos.
|
18519639 |
2008 |
|
Alzheimer's Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
We suggest that alterations of GDF11 and Tregs are involved in AD progression and that rejuvenation of the immune system is a potential therapeutic strategy in AD.
|
26317549 |
2015 |
|
Osteoporosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
GDF11 level is significantly decreased in the plasma and bone marrow of aging mice and mice with osteoporosis.
|
25534870 |
2015 |
|
Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
We concluded that adeno-associated viruses-GDF11 and recombinant GDF11 protect against endothelial injury and reduce atherosclerosis in apolipoprotein E<sup>-/-</sup> mice, thus may be providing a novel approach to the treatment of atherosclerosis.
|
27502608 |
2016 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
We concluded that adeno-associated viruses-GDF11 and recombinant GDF11 protect against endothelial injury and reduce atherosclerosis in apolipoprotein E<sup>-/-</sup> mice, thus may be providing a novel approach to the treatment of atherosclerosis.
|
27502608 |
2016 |
|
Endothelial dysfunction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Here, we showed that adeno-associated viruses-GDF11 and recombinant GDF11 protein improve endothelial dysfunction, decrease endothelial apoptosis, and reduce inflammation, consequently decrease atherosclerotic plaques area in apolipoprotein E<sup>-/-</sup> mice.
|
27502608 |
2016 |
|
Atherosclerotic lesion
|
0.010 |
Biomarker
|
disease |
BEFREE |
GDF11 Protects against Endothelial Injury and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Null Mice.
|
27502608 |
2016 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Intracellular GDF11 retention adds to the concept of tumor-suppressor inactivation and reveals a cell-biological vulnerability for TNBCs lacking therapeutically actionable mutations.
|
29161592 |
2017 |
|
Cachexia
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
The TGF-β family ligands myostatin, GDF11, and activins are negative regulators of skeletal muscle mass, which have been reported to primarily signal via the ActRIIB receptor on skeletal muscle and thereby induce muscle wasting described as cachexia.
|
29109273 |
2017 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Since its discovery in 1999, studies have shown the involvement of GDF11 in normal physiological processes, such as embryonic development and erythropoiesis, as well as in the pathophysiology of aging, cardiovascular disease, diabetes mellitus, and cancer.
|
29113418 |
2017 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Since its discovery in 1999, studies have shown the involvement of GDF11 in normal physiological processes, such as embryonic development and erythropoiesis, as well as in the pathophysiology of aging, cardiovascular disease, diabetes mellitus, and cancer.
|
29113418 |
2017 |
|
Cardiovascular Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The latest studies have shown that the level of circulating GDF 11 correlates with the outcomes of patients with cardiovascular diseases, cancer and uremia.
|
28223232 |
2017 |
|
Cardiovascular Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Administration of GDF11 may be an efficacious therapy to protect against cardiovascular diseases in splenectomized patients.
|
27565745 |
2017 |
|
Chronic Obstructive Airway Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Decrease in an anti-ageing factor, growth differentiation factor 11, in chronic obstructive pulmonary disease.
|
28455454 |
2017 |
|
Myocardial Infarction
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Young (3 months) and old (21 months) mice were used to evaluate the expression of GDF11 mRNA in the myocardium at baseline and after ischemia/reperfusion (I/R) and myocardial infarction.
|
28004242 |
2017 |
|
Obesity
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We firstly confirmed that the expression of GDF11 decreased both in the skeletal muscle of obese mice and palmitate-treated myotubes, but supplementation GDF11 does not ameliorate the palmitate-induced insulin resistance in C2C12 myotubes.
|
28485800 |
2017 |